Fig. 1From: Tumor-targeting, Systemically Delivered Antisense HER-2 Chemosensitizes Human Breast Cancer Xenografts Irrespective of HER-2 LevelsComparison of the uptake of AS HER-2 ODN complexed with five different liposome formulations in MDA-MB-435 FF cells. MDA-MB-435 FF cells, MDA-MB-435 cells grown in folate-free medium at least for 3 weeks.Back to article page